Jeffrey Cutler
Otolaryngic Allergy · Denver, CONPI 1114941358
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 31 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 19.0% — the pattern of someone who eats at a lot of different presentations.
Across 31 payments — averaging $19.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$114
- Kaleo, Inc.$93
- Regeneron Healthcare Solutions, Inc.$89
- Sanofi$86
- Stryker$64
- Neurent Medical Limited$36
- plus $118 from 5 others
Across 3 payments — averaging $371.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$1K
What the payments were for
- Food & beverage$601100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 7 | $114 |
| Kaleo, Inc. | 5 | $93 |
| Regeneron Healthcare Solutions, Inc. | 4 | $89 |
| Sanofi | 4 | $86 |
| Stryker | 3 | $64 |
| Neurent Medical Limited | 1 | $36 |
| Medtronic | 2 | $34 |
| Optinose US, Inc. | 2 | $31 |
| Johnson & Johnson | 1 | $19 |
| Amgen | 1 | $18 |
| Novartis | 1 | $16 |
How this compares
Too few otolaryngic allergy providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent SyringeDupilumab | 12 | $40,801 |
| Ipratropium Bromide | 324 | $10,452 |
| Azelastine Hcl | 209 | $6,608 |
| Mupirocin | 327 | $3,480 |
| Mometasone Furoate | 12 | $1,968 |
| Pilocarpine Hcl | 19 | $1,269 |
| Doxycycline Hyclate | 45 | $643 |
| Montelukast Sodium | 55 | $625 |
| Ondansetron OdtOndansetron | 43 | $531 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 47 | $516 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 36 | $278 |
| Prednisone | 143 | $243 |
| Levofloxacin | 16 | $61 |
Paid to pharmacies, not to this prescriber.
Other otolaryngic allergy in Denver
- Edward HepworthDenver$9K
- Kristen FahrnerSteamboat Springs$484
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.